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Abstract
Background: Most evidence for TSC-associated neuropsychiatric disorders (TAND) to date have come from small
studies and case reports, and very little is known about TAND in adults. We explored baseline TAND data from the
large-scale international TOSCA natural history study to compare childhood and adult patterns, describe age-based
patterns, and explore genotype-TAND correlations.
Results: The study enrolled 2216 eligible participants with TSC from 170 sites across 31 countries at the data cut-off
for the third interim analysis (data cut-off date: September 30, 2015). The most common behavioural problems
(reported in > 10% of participants) were overactivity, sleep difficulties, impulsivity, anxiety, mood swings, severe
aggression, depressed mood, self-injury, and obsessions. Psychiatric disorders included autism spectrum disorder
(ASD, 21.1%), attention deficit hyperactivity disorder (ADHD, 19.1%), anxiety disorder (9.7%), and depressive disorder
(6.1%). Intelligence quotient (IQ) scores were available for 885 participants. Of these, 44.4% had normal IQ, while
mild, moderate, severe, and profound degrees of intellectual disability (ID) were observed in 28.1, 15.1, 9.3, and 3.
1%, respectively. Academic difficulties were identified in 58.6% of participants, and neuropsychological deficits
(performance <5th percentile) in 55.7%. Significantly higher rates of overactivity and impulsivity were observed in
children and higher rates of anxiety, depressed mood, mood swings, obsessions, psychosis and hallucinations were
observed in adults. Genotype-TAND correlations showed a higher frequency of self-injury, ASD, academic difficulties
and neuropsychological deficits in TSC2. Those with no mutations identified (NMI) showed a mixed pattern of
TAND manifestations. Children and those with TSC2 had significantly higher rates of intellectual disability,
suggesting that age and genotype comparisons should be interpreted with caution.
Conclusions: These results emphasize the magnitude of TAND in TSC and the importance of evaluating for
neuropsychiatric comorbidity in all children and adults with TSC, across TSC1 and TSC2 genotypes, as well as in
those with no mutations identified. However, the high rates of unreported or missing TAND data in this study
underline the fact that, even in expert centres, TAND remains underdiagnosed and potentially undertreated.
Keywords: TSC-associated neuropsychiatric disorders, Tuberous sclerosis complex, TOSCA
* Correspondence: petrus.devries@uct.ac.za
1Division of Child and Adolescent Psychiatry, University of Cape Town, 46
Sawkins Road, Rondebosch, Cape Town 7700, South Africa
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
de Vries et al. Orphanet Journal of Rare Diseases  (2018) 13:157 
https://doi.org/10.1186/s13023-018-0901-8
Background
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant genetic disorder characterized by the formation of
hamartomas in multiple organ systems with a wide diver-
sity of symptoms and severity across individuals [1, 2].
The majority of individuals with TSC have central nervous
system involvement with a wide range of structural mani-
festations, such as cortical tubers, subependymal nodules,
and aberrations of gray and white matter as well as high
rates of functional manifestations, such as epilepsy, intel-
lectual disability (ID), and behavioural problems [3–5].
The neurological, neuropsychiatric, and renal manifesta-
tions represent the greatest burden of disease of all
TSC-related manifestations [3].
TSC-associated neuropsychiatric disorders (TAND) is
an umbrella term coined by the Neuropsychiatry Panel
of the 2012 International Consensus Conference for
TSC, and encompasses a range of neuropsychiatric man-
ifestations across various levels of investigation [2, 3, 5].
These include the behavioural level (observed behaviours
such as sleep problems or aggressive behaviours), the
psychiatric level (DSM/ICD defined psychiatric disorders
such as autism spectrum disorders [ASD] or attention
deficit hyperactivity disorder [ADHD]), the intellectual
level (intellectual ability as defined by intelligence quo-
tient [IQ]-type tests), the academic level (learning disor-
ders, e.g., reading or mathematics difficulties), and the
psychosocial level (e.g., self-esteem, family difficulties)
[3, 5, 6]. TAND represent a significant burden of disease
and have a major impact on quality of life of individuals
with TSC and their families, given their impact on edu-
cation, employment, and social life of patients and their
family [3, 5].
The rate and pattern of TAND vary greatly among pa-
tients with TSC [3, 5, 7–11]. Overall, about 90% of indi-
viduals with TSC exhibit TAND features to some extent
during their lifetime, with ASD and ID reported in up to
50% of individuals [3, 5, 6]. Results show differential
rates in those with and without ID [12]. However, even
individuals with normal intellectual abilities are at risk
of developing TAND manifestations, particularly in the
academic, neuropsychological, and psychosocial domains
[8]. Despite the high rates of TAND, a 2010 survey of
members of the Tuberous Sclerosis Association in the
United Kingdom indicated that only 20% of individuals
with TSC had ever received any assessment or treatment
for TAND, suggesting a large assessment and treatment
gap [5, 6, 12, 13]. It is important to acknowledge that
the majority of evidence for rates and patterns of TAND
to date have come from relatively small studies and case
reports. The largest published studies to date have in-
cluded a few hundred participants [10, 12, 14]. Further-
more, very little TAND data are available about adults
with TSC [15] or about the age-based pattern of TAND.
The underlying aetiology of TAND is likely to be com-
binatorial and multifactorial [16]. There is evidence that
the genetic aberrations of TSC may be sufficient to cause
TAND manifestations, [16, 17] with combinatorial and
interactive contribution from functional and structural
factors [16–22]. Individuals with TSC2 mutations have
been reported to have a greater likelihood of ID than
those with TSC1, [23–26] but both TSC1 and TSC2 mu-
tations have been associated with the full range of intel-
lectual ability from high IQ to profound ID [25, 26].
Individuals with no mutation identified (NMI) after gen-
etic testing have typically been described to have ID pro-
files between those with TSC1 and TSC2 [23–26]. These
studies have also been based on relatively small samples
and no study to date has examined other aspects of
TAND in relation to genotype.
The largest natural history study of TSC to date – the
TOSCA (TuberOus SClerosis registry to increase disease
Awareness) study is a multi-centre, international disease
registry designed with the aim of providing deeper insights
into the manifestations of TSC and its management [27,
28]. In a previous publication outlining baseline findings
from the TOSCA cohort of 2093 individuals, we presented
topline findings of TAND features in the largest TSC co-
hort reported globally to date [28]. Results showed that ID
was observed in 54% of the evaluated participants and
suggested that psychiatric disorders were typically diag-
nosed late. We also identified significant non-reported or
missing data, which suggested that even in expert TSC
centres around the globe, TAND may be underdiagnosed
and therefore under-treated [28].
Here, we performed a detailed exploration of the lar-
gest TAND dataset to date using TOSCA baseline data
of all the patients enrolled at the cut-off of September
30, 2015, with the specific aim of comparing childhood
and adult TAND profiles, describing the age-related pat-
tern of TAND, and examining TAND in relation to
genotype.
Methods
A detailed description of the methods of the TOSCA
registry has been provided previously [27]. In short, indi-
viduals of any age with a documented visit for TSC be-
fore 12 months of enrollment or newly diagnosed with
TSC were included in the study between August 2012
and August 2014.
Information on participant demography, family his-
tory, genotype, vital signs, prenatal history, clinical fea-
tures of TSC across all organ systems, comorbidities,
and rare manifestations were collected, both retrospect-
ively and prospectively at baseline and annually there-
after for up to 5 years. Given that this was a natural
history study, participants were followed up based on
clinical need, and no clinical, laboratory or formal
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TAND evaluations were mandated by the protocol. The
terms and operationalization of TAND manifestations
and ‘levels’ were defined as in the primary TAND publi-
cation [5].
The TOSCA registry was designed and conducted in
accordance with the Guidelines for Good Clinical Prac-
tice and ethical principles outlined in the Declaration of
Helsinki [29, 30]. Written informed consent, with prior
endorsement by all local institutional review boards (hu-
man research ethics committees) was obtained from all
participants, parents, or guardians prior to registry
enrollment.
For the purposes of this manuscript, descriptive statis-
tics were used to summarize TAND data. Frequency of
TAND features were extracted and presented as percent-
age of individuals with available data (excluding
non-reported or missing data). Intellectual ability was
categorized as normal (IQ > 70), mild ID (IQ 51–70),
moderate ID (IQ 36–50), severe ID (IQ 20–35), and pro-
found ID (IQ < 20), according to DSM-5/ICD-10 [31,
32]. Psychiatric disorders were defined according to the
DSM-5/ICD-10. Age-based patterns of TAND (children
vs adults) and the association between TAND and geno-
type (TSC1 vs TSC2) were analyzed using Chi-square
test. The TOSCA study included data collection on all
levels of TAND as outlined above and summarised in
the primary TAND manuscript [5], apart from psycho-
social characteristics, such as self-esteem, sibling, or
family stressors, which were only included after the
TOSCA database was set up.
Results
A total of 2216 participants (1154 females and 1062
males) with TSC were enrolled into the TOSCA registry
from 170 sites across 31 countries at the data cut-off for
the third interim analysis (September 30, 2015). The me-
dian age of the TOSCA cohort was 13 years (range, < 1–
71) with 1410 individuals (63.6%) aged ≤18 years.
Overall TAND features
Table 1 and Fig. 1 represent the frequencies of TAND
features in the overall TOSCA cohort.
Behavioural level
The most common behavioural problems (reported in >
10% of participants) were overactivity (45%), sleep difficul-
ties (43.9%), impulsivity (42.7%), anxiety (33.3%), mood
swings (29.8%), severe aggression (24.3%), depressed mood
(19.2%), self-injury (15.5%), and obsessions (14%).
Psychiatric level
ASD was reported in 21.1% (314/1486), ADHD in 19.1%
(268/1404), anxiety disorder in 9.7% (133/1365), depres-
sive disorder in 6.1% (84/1371), and “other” psychiatric
disorders were reported in 8.4% (115/1377) of partici-
pants. The median age at diagnosis of neuropsychiatric
disorders were 5 years for ASD (mean, 7.8 years; range,
< 1–40), 6 years for ADHD (mean, 7.8 years; range, < 1–
38), 13.5 for anxiety disorder (mean, 17.4 years; range, <
1–50), 21 years for depressive disorder (mean, 24.3 years;
range, 3–49), and 11 years for “other” psychiatric disor-
ders (mean, 14.1 years; range, < 1–59).
Intellectual level
An IQ assessment was available for 885 participants
(39.9%). Of these, 393 participants (44.4%) had normal
intellectual ability, while mild, moderate, severe, and
profound degrees of ID were observed in 28.1% (249/
885), 15.1% (134/885), 9.3% (82/885), and 3.1% (27/885),
respectively.
Academic and neuropsychological levels
Academic/scholastic difficulties, classified as learning dis-
orders in DSM-5, such as mathematics, reading, writing,
or spelling, were noted in 58.6% (735/1254) of partici-
pants. Neuropsychological skills were formally assessed in
41.6% (564/1355) of participants, and neuropsychological
deficits (performance <5th percentile) were identified in
55.7% (314/564) of those evaluated.
TAND features in children vs adults
Some differences were observed in the frequencies of
TAND features between children (aged ≤18 years), and
adults (aged > 18 years) (Table 2). At the behavioural
level, the rates of overactivity and impulsivity were sig-
nificantly higher for children than adults (54.8% vs
21.4% and 46.7% vs 33.2% respectively, p < 0.001), while
rates of anxiety, mood swings, depressed mood, obses-
sions, psychosis and hallucinations were significantly
higher in adults than children (50.9% vs 25.8%; 40.8% vs
25.2%; 43.9% vs 8.2%; 19.2% vs 11.8%; 11.3% vs 3%;
10.3% vs 0.6%, respectively, P < 0.001 for all except ob-
sessions, P < 0.01). Interestingly, some behavioural mani-
festations showed similar rates in children and adults.
For instance, sleep difficulties and severe aggression
were very similar between children and adults (Table 2).
At the psychiatric level, ASD and ADHD were reported
at higher rates in children than in adults (23.1% vs
16.1%; 22.4% vs 10.5%; p = 0.0029 and P < 0.001 respect-
ively), while rates of anxiety disorder and depressive dis-
order were higher in adults than in children (16.8% vs
7%; 16.3% vs 2.1% respectively; P < 0.001). We observed
no major differences in the rates of academic difficulties
and neuropsychological skills between children and
adults (Table 2). However, highly significant difference
was observed between the rates of intellectual disability
between children and adults (Table 2).
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TAND features by age bands
Frequencies of all the TAND features by age bands at con-
sent are depicted in Table 3. The majority of TAND be-
havioural characteristics showed varying frequencies
across age bands, but anxiety and depressed mood showed
a clear pattern of increased frequency across increasing
age bands. Interestingly, the rates of diagnoses of anxiety
and depressive disorder showed a pattern that was not en-
tirely consistent with the behavioural observations for
anxiety and depressed mood. Severe and profound ID was
reported at low rates in the youngest age group (3%), in-
creasing in the under 10-year olds (6.6 and 9.7%), and ran-
ging between 12.7–19.3% in the older age bands.
TAND and genotype
Molecular testing for genetic mutations was performed
in 1000 participants (45.1%). Of them, 197 had TSC1
mutations, 644 had TSC2 mutations, and 144 had no
mutation identified (NMI). At the behavioural level,
TSC2 mutations were associated only with significantly
Table 1 TAND Features in the Overall TOSCA Cohort (N = 2216)
TAND Features Individuals With Manifestation,
n (%)a
Individuals With Available Data,
n (%)
Individuals with Data
Not Available*, n (%)
Behavioural level
Overactivity 337 (45.0) 749 (33.8) 1467 (66.2)
Sleep difficulties 331 (43.9) 754 (34.0) 1462 (66.0)
Impulsivity 317 (42.7) 742 (33.5) 1474 (66.5)
Anxiety 240 (33.3) 720 (32.5) 1496 (67.5)
Mood swings 214 (29.8) 718 (32.4) 1498 (67.6)
Severe aggression 183 (24.3) 754 (34.0) 1462 (66.0)
Depression mood 139 (19.2) 724 (32.7) 1492 (67.3)
Self-injury 117 (15.5) 755 (34.1) 1461 (65.9)
Obsessions 100 (14.0) 714 (32.2) 1502 (67.8)
Psychosis 40 (5.5) 725 (32.7) 1491 (67.3)
Hallucinations 26 (3.6) 719 (32.5) 1497 (67.5)
Psychiatric level
ASD 314 (21.1) 1486 (67.1) 730 (32.9)
ADHD 268 (19.1) 1404 (63.4) 812 (36.6)
Anxiety disorder 133 (9.7) 1365 (61.6) 851 (38.4)
Depressive disorder 84 (6.1) 1371 (61.9) 845 (38.1)
Intellectual level
Normal 393 (44.4) 885 (39.9) 1331 (60.1)
Mild ID 249 (28.1) 885 (39.9) 1331 (60.1)
Moderate ID 134 (15.1) 885 (39.9) 1331 (60.1)
Severe ID 82 (9.3) 885 (39.9) 1331 (60.1)
Profound ID 27 (3.1) 885 (39.9) 1331 (60.1)
Academic level
Individuals ever had difficulties in academic
performance
735 (58.6) 1254 (56.6) 962 (43.4)
Individuals assessed for academic difficulties 359 (48.8)b NA NA
Neuropsychological level
Individuals ever had any neuropsychological
skill assessed
564 (41.6) 1355 (61.1) 861 (38.9)
Individuals with performance <5th percentile 314 (55.7)c NA NA
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, NA not applicable, TAND TSC-
associated neuropsychiatric disorders
*Missing data includes unknown option ticked for TAND features in eCRF by patient/investigator
aPercentages calculated considering only available data and excluding missing data unless otherwise specified
bPercentages calculated based on the number of individuals with reported academic difficulties as denominator
cPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator
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higher frequency than TSC1 for self-injury (15.8% vs
6.3%, P = 0.0288; Table 4). At the psychiatric level, ASD
was observed at significantly higher frequency in partici-
pants with TSC2 than those with TSC1 mutations
(28.6% vs 12.2%, P < 0.001). ADHD, anxiety disorder and
depressive disorder were not significantly different be-
tween the two genotypes, but it was interesting to ob-
serve that all three showed higher absolute frequencies
in association with TSC1 rather than TSC2 (ADHD
TSC1 = 17.6%; TSC2 = 16%, P = 0.6881; Anxiety disorder
TSC1 = 10.1%; TSC2 = 8.6%; P = 0.7809; Depressive dis-
orders TSC1 = 10%; TSC2 = 5.2%; P = 0.0509) (Table 4).
The frequencies in behavioural and psychiatric manifes-
tations of individuals with NMI ranged sometimes be-
tween and sometimes higher or lower than TSC1 and
TSC2 (Table 4).
Of the 93 participants with TSC1 mutation who
had been evaluated using IQ-type tests, 62 (66.7%)
had normal intellectual ability, 15 (16.1%) had mild
ID, 11 (11.8%) had moderate ID, 5 (5.4%) had severe
ID, and no participant had profound ID. Among 293
participants with TSC2 mutation who had been evalu-
ated using IQ-type tests, 123 (42%) had normal intel-
lectual ability, 75 (25.6%) had mild ID, 57 (19.5%) had
moderate ID, 30 (10.2%) had severe ID, and 8 (2.7%)
had profound ID. Significant difference was observed
between TSC1 and TSC2 groups for IQ levels/cat-
egories. (P = 0.001, Table 4).
Academic/scholastic difficulties were more common in
individuals with TSC2 mutation than those with TSC1
mutation (63.5% vs 49.2%; P = 0.0051, Table 4). More in-
dividuals with TSC2 mutation had neuropsychological
performance scores falling below the 5th percentile com-
pared to those with TSC1 mutation (63% vs 38.8%, P =
0.0024). Individuals with NMI showed IQ, academic and
neuropsychological profiles in between the frequencies
of the group with TSC1 and TSC2.
Discussion
The TOSCA registry allowed exploration of the fre-
quency of a wide range of TAND features in the lar-
gest cohort of TSC reported to date. We set out to
examine the overall TAND profile, to compare child-
hood and adult patterns, age-based patterns, and
genotype-TAND correlations. Results showed lower
rates of behavioural and psychiatric disorders than
previously reported, but similar rates of ID [3, 6, 8,
12]. The very high rates of non-reported or missing
data in this study (in excess of 60% for behavioural
and intellectual levels) may, at least in part, have con-
tributed to the lower rates observed. The rates of aca-
demic difficulties and neuropsychological deficits,
reported in this study for the first time, were very
high and suggested that between half and two-thirds
of individuals with TSC will have difficulties in these
two TAND levels. In spite of relatively similar rates
of ID between children and adults, we observed a pat-
tern of higher overactivity and impulsivity in children, and
higher rates of anxiety and depressed mood in adults. Inter-
estingly, some TAND characteristics such as sleep problems
Fig. 1 Summary of TAND Findings from the TOSCA Study (N = 2216)
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and severe aggression remained high across all age bands,
suggesting persistence of these difficulties across the life-
span. With regards to genotype-TAND correlations, we ob-
served a genotype-intellectual phenotype correlation and a
higher frequency of ASD in association with TSC2, similar
to previous reports [8, 26]. Interestingly, fewer other
TAND-genotype correlations were observed. Self-injury,
ASD, academic difficulties and neuropsychological deficits
were the only other significant correlations with TSC2.
Given that all of these are known to be strongly correlated
with intellectual level [12], and given the differences ob-
served here in IQ groups, these results have to be treated
with caution and should be explored in relation to matched
or stratified IQ groups in future studies. We also observed
a potential pattern of more depressed and anxious mood,
and higher rates of anxiety and depressive disorders in asso-
ciation with TSC1 mutations. This was a novel observation
not previously reported in the literature, but the same
Table 2 TAND Features in Children vs Adults
TAND Features Children (≤ 18 Years) With
Manifestation, (n = 1410)
n (%)
Adults (> 18 Years) With
Manifestation, (n = 806)
n (%)
p value
Behavioural levela
Overactivity 290 (54.8) 47 (21.4) < 0.0001
Sleep difficulties 225 (43.4) 106 (45.1) 0.6531
Impulsivity 244 (46.7) 73 (33.2) 0.0006
Anxiety 130 (25.8) 110 (50.9) < 0.0001
Mood swings 128 (25.2) 86 (40.8) < 0.0001
Severe aggression 121 (22.9) 62 (27.4) 0.1850
Depressed mood 41 (8.2) 98 (43.9) < 0.0001
Self-injury 73 (13.9) 44 (19.2) 0.0625
Obsessions 59 (11.8) 41 (19.2) 0.0085
Psychosis 15 (3.0) 25 (11.3) < 0.0001
Hallucinations 3 (0.6) 23 (10.3) < 0.0001
Psychiatric levela
ASD 246 (23.1) 68 (16.1) 0.0029
ADHD 227 (22.4) 41 (10.5) < 0.0001
Anxiety disorder 68 (7) 65 (16.8) < 0.0001
Depressive disorder 21 (2.1) 63 (16.3) < 0.0001
Intellectual levelb
Normal IQ 283 (43.5) 110 (47.0)
Mild ID 202 (31) 47 (20.1)
Moderate ID 101 (15.5) 33 (14.1) 0.0005e
Severe ID 51 (7.8) 31 (13.2)
Profound ID 14 (2.2) 13 (5.6)
Academic level
Individuals ever had difficulties in academic performancea 506 (60.5) 229 (54.8) 0.0517
Individuals assessed for academic difficultiesc 273 (54.0)c 86 (37.6)c 0.0785
Neuropsychological level
Individuals ever had any neuropsychological skill assesseda 414 (42.5) 150 (39.4) 0.2926
Individuals with performance <5th percentiled 235 (56.8)d 79 (52.7)d 0.5333
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated
neuropsychiatric disorders
aPercentages calculated considering only available data and excluding missing data unless otherwise specified
bPercentages calculated based on the number of individuals with IQ assessment available in each age group: ≤ 18 years, n = 585; > 18, n = 234)
cPercentages calculated based on the number of individuals with reported academic difficulties as denominator
dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator
eChi-square test showing association between children and adults across all levels of IQ
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caveat in relation to IQ as potential confounder requires ex-
ploration in future studies. The TAND profile of individuals
with NMI was also a novel finding. Intellectual, academic
and neuropsychological profiles seemed to fall between the
frequencies of those with TSC1 and TSC2 mutations, map-
ping onto intellectual findings previously reported [8, 26].
However, the same pattern was not seen in behavioural and
psychiatric manifestations.
About 7% of individuals in the general population are
expected to have clinically significant behavioural prob-
lems [33]. However, much higher rates of behavioural
difficulties are reported in patients with TSC [7]. In a
Table 3 TAND Features According to Age Bands (Based on Age at Consent)
TAND Features Age at Registry Consent, Years
≤ 2 > 2to≤ 5 > 5 to≤ 9 > 9 to≤ 14 > 14 to≤ 18 > 18 to≤ 40 > 40
n = 283 n = 301 n = 335 n = 307 n = 184 n = 579 n = 227
Behavioural levela
Overactivity 21 (53.8) 77 (65.3) 94 (60.6) 67 (47.5) 31 (40.8) 41 (23.7) 6 (12.8)
Sleep difficulties 24 (64.9) 43 (38.4) 61 (40.7) 68 (48.6) 29 (36.3) 70 (38.5) 36 (67.9)
Impulsivity 12 (31.6) 54 (47.4) 79 (52.0) 70 (49.3) 29 (38.2) 67 (38.3) 6 (13.3)
Anxiety 2 (5.6) 24 (21.2) 33 (22.9) 45 (33.3) 26 (34.2) 74 (44.6) 36 (72)
Mood swings 5 (13.5) 18 (16.1) 39 (25.8) 36 (27.1) 30 (40.5) 77 (46.4) 9 (20)
Severe aggression 2 (5.4) 15 (13.0) 45 (29.2) 40 (27.8) 19 (24.4) 57 (31.7) 5 (10.9)
Depression mood 0 0 10 (6.9) 17 (12.7) 14 (18.7) 68 (40.2) 30 (55.6)
Self-injury 3 (7.9) 9 (7.8) 28 (18.7) 23 (16.1) 10 (12.7) 37 (20.6) 7 (14.3)
Obsessions 2 (5.6) 7 (6.3) 15 (10.3) 22 (16.3) 13 (17.6) 33 (19.9) 8 (17.0)
Psychosis 0 2 (1.8) 4 (2.8) 7 (5.2) 2 (2.6) 22 (12.6) 3 (6.3)
Hallucinations 0 0 0 3 (2.3) 0 21 (11.9) 2 (4.3)
Psychiatric levela
ASD 18 (10.8) 49 (22.9) 73 (26.2) 68 (26.3) 38 (26) 65 (18.6) 3 (4.2)
ADHD 11 (7.1) 50 (24.2) 82 (31.1) 61 (24.5) 23 (16.7) 39 (12.1) 2 (2.9)
Anxiety disorder 1 (0.6) 8 (3.9) 15 (5.9) 31 (13.1) 13 (10.4) 51 (16.1) 14 (19.7)
Depressive disorder 0 3 (1.4) 2 (0.8) 8 (3.4) 8 (6.3) 44 (14.2) 19 (25)
Intellectual levelb
Normal IQ 37 (56.1) 72 (52.9) 74 (39.8) 64 (37.9) 36 (38.3) 82 (42.7) 28 (66.7)
Mild ID 18 (27.3) 38 (27.9) 58 (31.2) 56 (33.1) 32 (34.0) 43 (22.4) 4 (9.5)
Moderate ID 9 (13.6) 17 (12.5) 36 (19.4) 25 (14.8) 14 (14.9) 30 (15.6) 3 (7.1)
Severe ID 1 (1.5) 9 (6.6) 13 (7.0) 18 (10.7) 10 (10.6) 27 (14.1) 4 (9.5)
Profound ID 1 (1.5) 0 5 (2.7) 6 (3.6) 2 (2.1) 10 (5.2) 3 (7.1)
Academic level
Individuals ever had difficulties in
academic performancea
1 (1.3) 48 (36.9) 167 (69.3) 193 (75.7) 97 (73.5) 195 (59.6) 34 (37.4)
Individuals assessed for academic
difficultiesc
0 20 (41.7) 93 (55.7) 103 (53.4) 57 (58.8) 77 (39.5) 9 (26.5)
Neuropsychological level
Individuals ever had any
neuropsychological skill assesseda
31 (20.4) 69 (32.4) 121 (48.2) 124 (53.2) 69 (55.2) 129 (42.7) 21 (26.6)
Individuals with performance <5th
percentiled
12 (38.7) 35 (50.7) 69 (57.0) 78 (62.9) 41 (59.4) 72 (55.8) 7 (33.3)
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, IQ intelligence quotient, ID intellectual disability, TAND TSC-associated
neuropsychiatric disorders. Values are expressed as n (%)
aPercentages calculated considering only available data and excluding missing data
bPercentages calculated considering individuals with IQ assessment available in each age group: ≤ 2 years (n = 66); > 2 to ≤5 years (n = 136); > 5 to ≤9 (n = 186); >
9 to ≤14 (n = 169); > 14 to ≤18 (n = 94); > 18 to ≤40 (n = 192); > 40 (n = 42)
cPercentages calculated based on the number of individuals with reported academic difficulties as denominator
dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator
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pilot validation study of the TAND checklist, all the par-
ticipants (n = 62) had reported at least one lifetime
TAND behavioural difficulty, 97% had ≥2 behavioural
difficulties and 89% reported ≥6 behavioural difficulties
[6]. The findings in this large-scale international study
confirm the high rates of a wide range of behavioural
Table 4 TAND Features by Genotype*
TAND Features Individuals With TSC1
Mutation
(n = 197)
n (%)a
Individuals With TSC2
Mutation,
(n = 644)
n (%)a
Individuals With no TSC
Mutation Identified (NMI),
(n = 144)
n (%)a
Statistical difference
between TSC1 and TSC2
p Valuee
Behavioural level
Overactivity 27 (40.9) 112 (43.4) 24 (45.3) 0.8788
Sleep difficulties 31 (48.4) 129 (50.6) 30 (54.5) 0.5656
Impulsivity 32 (49.2) 107 (41.6) 23 (45.1) 0.1773
Anxiety 24 (38.7) 82 (33.6) 17 (34.0) 0.5519
Mood swings 14 (21.5) 64 (26.6) 15 (29.4) 0.4907
Severe aggression 14 (21.2) 56 (21.5) 11 (20.8) 0.9290
Depression mood 15 (24.2) 46 (18.7) 12 (23.5) 0.2651
Self-injury 4 (6.3) 41 (15.8) 8 (14.5) 0.0288
Obsessions 8 (13.1) 35 (14.2) 8 (16.0) 0.9140
Hallucinations 3 (4.8) 7 (2.8) 2 (3.9) 0.3960
Psychosis 4 (6.5) 9 (3.6) 3 (5.8) 0.2865
Psychiatric level
ASD 18 (12.2) 138 (28.6) 17 (17.5) < 0.0001
ADHD 24 (17.6) 72 (16.0) 14 (14.9) 0.6881
Anxiety disorder 14 (10.1) 38 (8.6) 8 (9.2) 0.7809
Depressive disorder 14 (10.0) 23 (5.2) 7 (8.0) 0.0509
Intellectual levelb
Normal IQ 62 (66.7) 123 (42.0) 41 (64.1)
Mild ID 15 (16.1) 75 (25.6) 14 (21.9)
Moderate ID 11 (11.8) 57 (19.5) 3 (4.7) 0.001f
Severe ID 5 (5.4) 30 (10.2) 6 (9.4)
Profound ID 0 8 (2.7) 0
Academic level
Individuals ever had difficulties
in academic performance
63 (49.2) 240 (63.5) 53 (58.2) 0.0051
Individuals assessed for
academic difficulties
34 (54.0)c 132 (55.0)c 25 (47.2)c 0.5391
Neuropsychological level
Individuals ever had any
neuropsychological skill
assessed
67 (51.1) 216 (49.4) 46 (51.1) 0.7697
Individuals with performance
<5th percentile
26 (38.8)d 136 (63.0)d 19 (41.3)d 0.0024
ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, ID intellectual disability, IQ intelligence quotient, TAND TSC-associated
neuropsychiatric disorders
*Molecular testing for genetic mutations was performed in 1000 (45.1%) individuals. Of these, 644 (64.4%) had a TSC2 gene mutation, 197 (19.7%) had a TSC1
gene mutation, 6 had both TSC1 and TSC2 gene mutations and 144 (14.4%) had no mutations. Data were not available for 9 individuals
aPercentages calculated considering only available data and excluding missing data unless otherwise specified
bPercentages calculated considering individuals with IQ assessment available in each group: Individuals with TSC1 mutation, n = 93; individuals with TSC2
mutation, n = 293)
cPercentages calculated based on the number of individuals with reported academic difficulties as denominator
dPercentages calculated based on the number of individuals who had neuropsychological skill assessed as denominator
eTSC1 vs TSC2
fChi-square test showing association between children and adults across all levels of IQ
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problems in TSC. The comparison between children and
adults showed a pattern of lower overactive/impulsive
behaviours in adults but higher anxiety or depressed
mood. These findings map well onto typical age-based
expectations in psychopathology [8, 9, 12]. However, our
results also highlighted the fact that behavioural difficul-
ties occurred across all ages in individuals with TSC.
These findings underline the importance of expecting and
evaluating for a changing profile of TAND difficulties
from childhood into adulthood, as recommended in
TAND assessment guidelines [2, 34, 35].
Among the psychiatric problems associated with TSC,
ASD, and ADHD are the most common neurodevelop-
mental disorders in children, and anxiety/mood disorders
the most common in adults [8]. The variable rates of ASD
(17–68%) and ADHD (30–60%) reported in earlier studies
can be understood based on different study methodolo-
gies, diagnostic criteria used, and level of intellectual abil-
ity of participants [7, 8, 36]. In this study, ASD and
ADHD were reported in 21.1% and 19.1% of participants,
respectively. As highlighted in our baseline paper [27] the
diagnosis of ASD, in particular, was made very late (mean
age, 7.8 years; median age, 5 years; range, 0–38 years) [28].
In spite of very high rates of anxiety and depressed mood
symptoms in the cohort, the rates of diagnoses of anxiety
disorders or depressive disorders were surprisingly low in
our study (anxiety disorder, 9.7%; depressive disorder,
6.1%). Taking together the high rates of non-reported or
missing data, late ages of diagnoses and frequencies ob-
served in our cohort, we suggest that psychiatric disorders
are underdiagnosed and potentially diagnosed late in indi-
viduals with TSC. The low rates of ASD and ADHD ob-
served in adults here, may suggest a cohort effect where
adults were not assessed for developmental disorders in
the past decades.
In line with previous reports, [8, 26, 37] the TOSCA
registry showed a genotype-intellectual phenotype pat-
tern suggesting a greater likelihood of ID in participants
with TSC2 than those with TSC1 mutations. However, it
was also important to note that only 66.7% of those with
TSC1 had normal intellectual ability, suggesting that a
third of individuals with TSC1 may have ID. Similarly,
even though TSC2 mutations were more likely to be as-
sociated with ID, 42% of all individuals with TSC2 muta-
tions had normal intellectual ability. Our findings
therefore reinforce the message that genotype (TSC1 vs
TSC2) is not a clinically helpful predictor of intellectual
ability at an individual level [26].
The differences between those with TSC1 and TSC2
mutations observed in other aspects of TAND were of
interest, particularly as all previous genotype-phenotype
studies have suggested a more “severe” phenotype asso-
ciated with TSC2 [38]. The possibility that specific as-
pects of TAND may be more likely in association with
TSC1 is therefore a potentially important observation.
We acknowledge that a TSC1 vs TSC2 differentiation
may be highly oversimplistic, given that specific TSC
mutations may be associated with very different func-
tional consequences at a biochemical level [16, 26].
The challenge around unreported and missing TAND
data in this study was significant. Fewer than 40% of be-
havioural data were available and only 39.9% of partici-
pants in the TOSCA registry received an evaluation of
their intellectual ability. The overall rates of ID were
consistent with previous studies, [8, 12] but we did not
observe a bimodal distribution of intellectual ability as
previously reported [23, 25, 39, 40]. Given that only
about half of the TOSCA cohort received a formal evalu-
ation for IQ, it is possible that more severely impaired
individuals may not have been referred for an assess-
ment of their intellectual or developmental quotient (as
was done in the population-based study that observed
the clear bimodal pattern) [39]. Academic data were not
reported or were missing in 43.4% of the cohort and
38.9% were not reported or were missing regarding
neuropsychological skills. Only 48.8% of those with aca-
demic difficulties ever received evaluations, and only
41.6% were evaluated for neuropsychological deficits.
Whilst the very high rates of academic and neuro-
psychological deficits in TSC were a novel finding in the
TOSCA registry and underlines the recommendation
that all children with TSC should receive evaluation of
their academic and neuropsychological needs, [2, 35] the
very low proportion assessed raises significant clinical
concern.
Conclusions
Together, findings from the TOSCA registry emphasize
the magnitude of neuropsychiatric disorders in TSC,
which has an enormous impact on quality of life of indi-
viduals with TSC and their families. However, there was
a high proportion of non-reported or missing data,
which may have impacted the overall findings of the
study. Due to the observational nature of the registry,
only data already available from clinical practice were
collected. Moreover, considering the disease complexity
and the fact that individuals with TSC were not always
followed for all disease manifestations by the site in-
volved in the registry, ensuring report of all disease man-
ifestations of each participant was a major challenge. We
therefore acknowledge the potential ascertainment
biases that may come with large-scale clinic-based nat-
ural history studies such as this one.
There is clearly a highly dynamic interaction between
development, genotype, intellectual ability, epilepsy,
anti-epilepsy and other pharmacological treatments, and
environment in TSC. Future studies should therefore
aim to examine these interrelations in an integrated way
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using suitable multilevel computational modelling. We
also acknowledge that further evaluations will be re-
quired to examine TAND in relation to intellectual level
and sex. In addition, efforts are underway to determine
if there may be “natural TAND clusters” consisting of
natural groupings of TAND characteristics within and
between individuals with TSC across levels of TAND [7,
13]. The TOSCA cohort may provide a powerful dataset
to examine this possibility further.
In spite of the limitations inherent to a large-scale nat-
ural history study, results provide strong data to encour-
age clinicians to evaluate for neuropsychiatric comorbidity
in all children and adults with TSC. The 2012 TSC sur-
veillance and management guidelines recommend annual
screening for TAND [34]. A simple tool called the TAND
Checklist has been developed and validated in a pilot
study that could provide easy guidance to healthcare pro-
fessionals in assessing neuropsychiatric difficulties in each
individual with TSC [3, 5, 6].
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